Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092671506> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2092671506 endingPage "906" @default.
- W2092671506 startingPage "906" @default.
- W2092671506 abstract "Limb-girdle muscular dystrophy refers to a group of 23 disorders characterized by progressive wasting and weakness of shoulder and hip girdle muscles. The onset and progression of LGMD varies among individuals and genetic subtypes. Pre-clinical studies support that gene therapy is a promising treatment approach for the LGMDs, and importantly one such strategy (for LGMD2D) was recently translated to human clinical trials. Despite the positive direction of LGMD-targeted gene therapies, all strategies to date focused on gene replacement approaches for recessive forms, while treatments for dominant LGMDs have been largely unexplored. This lack of focus on gene therapy for dominant LGMDs arose primarily because these disorders require disease gene knockdown, and the molecular tools to feasibly accomplish this did not exist until recently, with the emergence of RNA interference (RNAi). We hypothesized that patients with dominantly inherited LGMD would benefit from RNAi-mediated reduction of the pathogenic alleles underlying their disease. In this study, we developed the first RNAi-based, pre-clinical treatment for LGMD1A, caused by dominant mutation in one allele of the myotilin (MYOT) gene. To do this, we engineered and delivered MYOT-targeted artificial microRNA (miMYOT) vectors to knockdown mutant MYOT in muscles of an LGMD1A mouse model. Three months after treatment, miMYOT vectors significantly reduced soluble mutant MYOT protein to undetectable levels, and the protein aggregates that are characteristic of LGMD1A were either absent or very small in treated muscles. This reduction was associated with significantly improved muscle mass and whole muscle strength in LGMD1A mice. We are now assessing body wide improvements of miMYOT treatment following global vascular delivery. This work is an important first step toward translating targeted RNAi gene therapy approaches for LGMD1A, and our method could be adapted to impact a large class of dominant muscle disorders." @default.
- W2092671506 created "2016-06-24" @default.
- W2092671506 creator A5005637071 @default.
- W2092671506 creator A5020523320 @default.
- W2092671506 creator A5047809221 @default.
- W2092671506 creator A5063322614 @default.
- W2092671506 creator A5066870896 @default.
- W2092671506 creator A5077119095 @default.
- W2092671506 date "2012-10-01" @default.
- W2092671506 modified "2023-10-05" @default.
- W2092671506 title "T.O.1 RNAi therapy for LGMD1A" @default.
- W2092671506 doi "https://doi.org/10.1016/j.nmd.2012.06.338" @default.
- W2092671506 hasPublicationYear "2012" @default.
- W2092671506 type Work @default.
- W2092671506 sameAs 2092671506 @default.
- W2092671506 citedByCount "1" @default.
- W2092671506 countsByYear W20926715062023 @default.
- W2092671506 crossrefType "journal-article" @default.
- W2092671506 hasAuthorship W2092671506A5005637071 @default.
- W2092671506 hasAuthorship W2092671506A5020523320 @default.
- W2092671506 hasAuthorship W2092671506A5047809221 @default.
- W2092671506 hasAuthorship W2092671506A5063322614 @default.
- W2092671506 hasAuthorship W2092671506A5066870896 @default.
- W2092671506 hasAuthorship W2092671506A5077119095 @default.
- W2092671506 hasConcept C104317684 @default.
- W2092671506 hasConcept C111599444 @default.
- W2092671506 hasConcept C143065580 @default.
- W2092671506 hasConcept C166703698 @default.
- W2092671506 hasConcept C173396325 @default.
- W2092671506 hasConcept C180754005 @default.
- W2092671506 hasConcept C2778649560 @default.
- W2092671506 hasConcept C2779030066 @default.
- W2092671506 hasConcept C501734568 @default.
- W2092671506 hasConcept C54355233 @default.
- W2092671506 hasConcept C60644358 @default.
- W2092671506 hasConcept C67705224 @default.
- W2092671506 hasConcept C86803240 @default.
- W2092671506 hasConceptScore W2092671506C104317684 @default.
- W2092671506 hasConceptScore W2092671506C111599444 @default.
- W2092671506 hasConceptScore W2092671506C143065580 @default.
- W2092671506 hasConceptScore W2092671506C166703698 @default.
- W2092671506 hasConceptScore W2092671506C173396325 @default.
- W2092671506 hasConceptScore W2092671506C180754005 @default.
- W2092671506 hasConceptScore W2092671506C2778649560 @default.
- W2092671506 hasConceptScore W2092671506C2779030066 @default.
- W2092671506 hasConceptScore W2092671506C501734568 @default.
- W2092671506 hasConceptScore W2092671506C54355233 @default.
- W2092671506 hasConceptScore W2092671506C60644358 @default.
- W2092671506 hasConceptScore W2092671506C67705224 @default.
- W2092671506 hasConceptScore W2092671506C86803240 @default.
- W2092671506 hasIssue "9-10" @default.
- W2092671506 hasLocation W20926715061 @default.
- W2092671506 hasOpenAccess W2092671506 @default.
- W2092671506 hasPrimaryLocation W20926715061 @default.
- W2092671506 hasRelatedWork W101124211 @default.
- W2092671506 hasRelatedWork W1989617912 @default.
- W2092671506 hasRelatedWork W2044265296 @default.
- W2092671506 hasRelatedWork W2057739827 @default.
- W2092671506 hasRelatedWork W2070922469 @default.
- W2092671506 hasRelatedWork W2091920404 @default.
- W2092671506 hasRelatedWork W2099181930 @default.
- W2092671506 hasRelatedWork W2117110650 @default.
- W2092671506 hasRelatedWork W2223919059 @default.
- W2092671506 hasRelatedWork W3029967712 @default.
- W2092671506 hasVolume "22" @default.
- W2092671506 isParatext "false" @default.
- W2092671506 isRetracted "false" @default.
- W2092671506 magId "2092671506" @default.
- W2092671506 workType "article" @default.